AMD/RETINA
Long-term aflibercept injection achieve visual improvement and reduced the thickness of the retina and choroid in patients with neovascular age-related macular degeneration (nAMD), according to a study published in BMC Ophthalmology.
In this prospective study, 49 patients (50 eyes) with treatment-naïve nAMD received intravitreal aflibercept injection every 2 months for the first year before switching to a treat-and-extend approach in the subsequent 2 years.…
featured stories
View Conference Coverage
Take a look at some of our conference coverage, visit our roundup section.
Videos
-
Jan 22, 2020
Implantable Miniature Telescope for Advanced AMD
-
Jan 22, 2020
Treating AMD Patients with New Technology
-
Jan 22, 2020
How do you Verify That a Patient Has AMD?
-
Jan 22, 2020
Age-related Drusen or Pathologic Drusen?
-
Jan 22, 2020
What is DME?
-
Jan 22, 2020
ENTV DME Treatment Strategy
Conference Roundup
- May 14, 2020
ASRS Annual Meeting to be Held Virtually
The American Society of Retina Specialists (ASRS) will hold its annual meeting online from July 24-26, 2020.
In a letter to ASRS members, Timothy Murray, MD, MBA, ASRS…
Journal Scan
- Jul 14, 2020
Visual acuity improvement after aflibercept injection maintained over 3 years
Long-term aflibercept injection achieve visual improvement and reduced the thickness of the retina and choroid in patients with neovascular age-related macular degeneration (nAMD), according to a study published in BMC Ophthalmology. …
Trending Topics
- Jun 26, 2020
FDA rejects Abicipar pegol for treatment of wet AMD
The U.S. Drug and Food Administration has rejected a new drug application for Abicipar pegol, a neovascular (wet) age-related macular degeneration (AMD). drug…
Resources
-
Eye Care Tools
- AAO Eye Wiki
- AAO Patient Education Materials
- ASRS Retina Career Center